Evofem Biosciences (NASDAQ:EVFM – Get Rating) was downgraded by Stifel Nicolaus from a "buy" rating to a "hold" rating in a research note issued to investors on Wednesday, The Fly reports.
Separately, HC Wainwright raised their price target on shares of Evofem Biosciences to $4.00 and gave the stock a "buy" rating in a research note on Monday, August 15th.
Get Evofem Biosciences alerts:Evofem Biosciences Stock Down 5.2 %
Shares of EVFM opened at $0.09 on Wednesday. The stock has a market capitalization of $9.57 million, a P/E ratio of 0.00 and a beta of -0.93. Evofem Biosciences has a twelve month low of $0.08 and a twelve month high of $11.20. The company has a 50 day moving average of $0.32 and a 200-day moving average of $1.30.
Evofem Biosciences (NASDAQ:EVFM – Get Rating) last issued its quarterly earnings results on Friday, August 12th. The biotechnology company reported ($4.57) earnings per share for the quarter, missing the consensus estimate of ($1.01) by ($3.56). The firm had revenue of $6.03 million for the quarter, compared to the consensus estimate of $5.80 million. On average, sell-side analysts anticipate that Evofem Biosciences will post -2.31 earnings per share for the current fiscal year.Institutional Investors Weigh In On Evofem Biosciences
A hedge fund recently raised its stake in Evofem Biosciences stock. State Street Corp increased its stake in Evofem Biosciences, Inc. (NASDAQ:EVFM – Get Rating) by 4.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 393,070 shares of the biotechnology company's stock after buying an additional 17,021 shares during the quarter. State Street Corp owned approximately 3.23% of Evofem Biosciences worth $134,000 as of its most recent SEC filing. Institutional investors and hedge funds own 13.49% of the company's stock.
About Evofem Biosciences
(Get Rating)
Evofem Biosciences, Inc, a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100, an antimicrobial vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection and Neisseria gonorrhoeae infection in women.
Featured Stories
- Get a free copy of the StockNews.com research report on Evofem Biosciences (EVFM)
- Does the Zillow Stock Forecast Hint Toward a Turnaround?
- Will MGM Resorts Rise to the Top of the Casino Food Chain?
- Does Short Selling In AMC Mean The Stock Is A Horror Movie?
- The Rally in Walgreen's Boots Alliance May be Short Lived
- Domino's Pizza Rises To The Occasion In Q3
Receive News & Ratings for Evofem Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evofem Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.